 ## Bill Ackman and the Entire Team Invested $311 Million in PSUS — What Does This Mean? Yesterday, an event occurred that I rarely see: the CEO + CIO + President + CFO + CCO + Trustee + Secretary of one company — all bought shares simultaneously. Not options, not bonuses — personal money on the open market. ### Pershing Square USA (PSUS): Figures for April 30 | Who | Position | Bought | Price | Amount | |---|---|---|---|---| | William Ackman | CEO | 4,897,171 shares | $49.18 | $240.8 million | | Ryan Israel | CIO | 500,000 | $50.00 | $25 million | | Ben Hakim | President | 350,000 | $50.00 | $17.5 million | | Nicholas Botta | Trustee | 250,000 | $50.00 | $12.5 million | | Halit Coussin | CCO | 200,000 | $50.00 | $10 million | | Michael Gonnella | CFO | 100,000 | $50.00 | $5 million | | Jessica Falzone | Secretary | 2,000 | $50.00 | $100k | Total: $311 million in insider purchases in one day. All opened new positions — they had no PSUS shares before. ### Why This Matters Pershing Square USA is Ackman's new ticker after converting his SPAC (PSTH) into a corporation. The company holds a concentrated portfolio of ~8-12 major positions (Alphabet, Chipotle, Hilton, etc.). When the entire C-level team synchronously buys at $50 — this is not speculation. It is internal confidence that the current price is below fair value. Ackman personally contributed $240 million — for him, this is not pocket change, but a signal of maximum clarity. ### What Else Is Notable In parallel: - S&P Global (SPGI): CEO Martina Cheung bought 2,322 shares at $430 — the first purchase by the CEO in a long time - Textron (TXT): a director doubled their position, buying 10,300 shares - GE Healthcare (GEHC): CFO bought $200k worth - Avalyn Pharma (AVLN): a fund + director bought $15 million at $18 ### My Position A massive synchronous purchase by top management is one of the strongest bullish signals. If people who know the business from the inside simultaneously put in personal money — the market usually catches up later. I will be watching PSUS in the coming weeks. Data: OpenInsider, 05/01/2026. Not an investment recommendation.